

# JAMP Abiraterone

Reference product ZYTIGA®



<b>Therapeutic use</b>	<b>Androgen Biosynthesis Inhibitor</b>	
<b>Indication<sup>1</sup></b>	Indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer, mCRPC) in patients who: <ul style="list-style-type: none"><li>- are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy</li><li>- have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy</li></ul> Also indicated in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed hormone-sensitive high-risk metastatic prostate cancer who may have received up to 3 months of prior ADT.	
<b>Active ingredient</b>	Abiraterone (as Abiraterone Acetate)	
<b>Dosage strength</b>	250 mg	500 mg
<b>DIN</b>	02502305	02525380
<b>Supplied</b>	120 count tablets	60 count tablets
<b>Storage conditions</b>	Store at 15°C to 30°C.	
<b>Shelf life</b>	48 M	

Consult the Product Monograph at [www.jampinfo.com](http://www.jampinfo.com) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

This document contains information only for residents of Canada. Please be aware that JAMP PHARM CORPORATION assumes no responsibility for access to and use of such information which may not comply with legal restrictions, regulations, registrations or intended use in the country if your origin. Eligibility restrictions and other terms and conditions may apply.

Reference: 1. JAMP Abiraterone Product Monograph. JAMP Pharma Corporation, February 16, 2022.

**FOR YOUR PATIENTS WITH metastatic prostate cancer (castration-resistant prostate cancer, mCRPC)<sup>†</sup> or newly diagnosed hormone-sensitive high-risk metastatic prostate cancer<sup>‡</sup>**

<sup>†</sup> in combination with prednisone, in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy or have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy

<sup>‡</sup> in combination with prednisone and androgen deprivation therapy (ADT), in patients who may have received up to 3 months of prior ADT

## The JAMP Care™ Patient Support Program

Provides the following benefits to your patients taking  
**JAMP Abiraterone**



**Reimbursement navigation**



**Bridging (as per provincial regulations)**



**Financial assistance (as per provincial regulations)**



**Renewal 3 months in advance**

**PLUS**



**Personalized consultation with a nutritionist (available on demand)**

JAMP Abiraterone	JAMP Care™	Other Programs
Reimbursement navigation	✓	✓
Bridging	✓	✓
Financial assistance	✓	✓
Renewal 3 months in advance	✓	
Personalized consultation with nutritionist (available on demand)	✓	
Patient education materials	✓	✓

\*Terms and conditions apply

### For more information on the JAMP Care Patient Support Program



Call toll-free: **1-855-310-5102**

Fax: **1-888-331-3432**

Monday to Friday, 8am to 8pm EST



Email: [jampcare@supportprogram.com](mailto:jampcare@supportprogram.com)



Visit: [www.jampcare-support.ca](http://www.jampcare-support.ca)

### For specific questions about JAMP Abiraterone



Call the JAMP Pharma Group Medical Information Department at 1-866-399-9091 Option 2



Email: [medinfo@jamppharma.com](mailto:medinfo@jamppharma.com)

Consult the Product Monograph at [www.jampinfo.com](http://www.jampinfo.com) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

Reference: 1. JAMP Abiraterone Product Monograph. JAMP Pharma Corporation, February 16, 2022.